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Data-independent Proteomic Screen Identifies Novel Tamoxifen
Agonist that Mediates Drug Resistance
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Abstract
A label-free quantitative variation of the recently developed data-independent shotgun proteomic
method Precursor Acquisition Independent From Ion Count (PAcIFIC) was used to identify novel
proteins implicated in cancer progression and resistance. Specifically, this screen identified the
pro-metastatic protein anterior gradient 2 (AGR2) as significantly up-regulated in tamoxifen
treated cells. Highlighting the need for direct proteome profiling methods like PAcIFIC, neither
data-dependent gas-phase fractionation nor a transcriptomic screen detected AGR2 protein/
transcript at significantly up-regulated levels. Further cell-based experiments using human cancer
cell lines and in vivo xenografts confirmed the PAcIFIC hypothesis that AGR2 is up-regulated in
MCF-7 cells post tamoxifen treatment, and that it is implicated in drug resistance mediation.
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Introduction
Cancer progression is driven in part by progressive accumulation of mutations in selected
proto-oncogenes and tumor suppressor genes that drive clonal cell evolution. Recent cancer
genomic sequencing has identified thousands of mutations in the cancer genome, some of
which have, or can, promote cancer cell survival.1–4 The cancer genome sequence itself
could be considered “static” and although it forms a record of the mutations that occurred
during the cancer progression sequence, this record may not reflect a priori the most
probable drug targets. Dynamic changes in the cancer cell transcriptome and proteome may
better reflect pathways or targets of interest on which to focus anti-cancer drug
development. Transcriptome approaches have been successful in identifying a large range of
genes up-regulated during metastasis and angiogenesis and continue to provide new insights
into clinically relevant carcinogenic mechanisms and drug targets. However, despite these
successes using transcriptomics to identify novel resistance factors, there can be up to 80%
**Requests for reprints: David R. Goodlett Ph. D. University of Washington, Box 357610, Seattle, WA 98105,
goodlett@u.washington.edu Phone: 206-616-4586 Fax: 206 685-3252.
*Current Address Pacific Northwest National Laboratory P.O. Box 999 MSIN K8-98, Richland, WA 99352 USA
Conflict of Interest
There are no financial or commercial conflicts of interest for any of the authors that contributed to this body of work.
Supporting Information
Supporting Information Available: This material is available free of charge via the Internet at http://pubs.acs.org
NIH Public Access
Author Manuscript
J Proteome Res. Author manuscript; available in PMC 2012 October 7.
Published in final edited form as:
J Proteome Res. 2011 October 7; 10(10): 4567–4578. doi:10.1021/pr2004117.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
disagreement in transcript and protein abundance.5–6 This discordance has dramatically
increased demand for proteomic screens to determine the active cellular processes
downstream from transcriptional events.
The many variations on the theme of shotgun proteomics used for proteome screens all
utilize upfront fractionation procedures prior to protein sequencing via tandem mass
spectrometry. These approaches include: i) SDS-PAGE, ii) chromatography, e.g. strong
cation exchange7 to enrich for broad classes of proteins and/or peptides and iii) affinity
matrices that can enrich or deplete protein-specific chemical moieties like phosphate or high
abundance proteins.8 These methods typically produce many fractions, each of which is then
subsequently analysed by data-dependent acquisition (DDA) driven HPLC-MS methods
which are known to under sample the peptides present in each fraction.9 Thus, no matter
how much fractionation is carried out, the end result is under sampling of each of the
fractions by DDA HPLC-MS/MS methods. Quantitative modifications of these approaches
include ex-vivo or in vivo labelling of proteins using fluorescent or stable isotopic chemical
tags in order to improve the sensitivity of the differential protein expression profile. The
remaining difficulty in applying these standard fractionation techniques followed by
proteomic profiling approaches to cancer biology and clinical medicine is the upfront
manipulation involved in processing for electrophoresis, liquid or gas phase separations, and
in vivo or ex-vivo labelling of proteins.
In addition to general proteomic profiling to define the components of a system, knowledge
of the relative protein abundance between experimental conditions is crucial to understand
the biological mechanisms that result from perturbations to the system. Unfortunately, many
of the most popular quantitative proteomic screening methods preclude direct analysis due
to requirement for fractionation (e.g. strong cation exchange separation of peptides) or
incorporation of stable isotopes, both of which can result in loss of protein during
preparation. The most popular methods include: i) Stable Isotope Labeling with Amino
acids in cell Culture (SILAC)10 which, due to the in vivo labelling protocol, is not possible
using primary human clinical biopsies, and ii) a large number of variations on the theme of
ex vivo labelling methods (e.g. iTRAQ11–12 and TMT13) each of which requires
fractionation prior to HPLC MS/MS analysis and concomitantly expands the number of
samples that must be examined often complicating experimental design.Advances that
streamline proteomic screens making them more similar to direct analysis without
fractionation of transcriptomics would facilitate clinical proteomics.
Recently a novel, data-independent acquisition (DIA), tandem mass spectrometry based
proteome screen referred to as Precursor Acquisition Independent From Ion Count
(PAcIFIC)14 was demonstrated to increase the identified proteomic dynamic range by an
order of magnitude when compared to the standard DDA shotgun proteomic methods. The
dynamic range benefit of PAcIFIC was gained by excluding pre-fractionation and use of
direct systematic interrogation of all m/z “channels” for the presence of peptides regardless
of the observation of a precursor ion. In combination this provides the DIA PAcIFIC method
with two advantages over DDA methods because 1) minimal sample handling decreases
nonspecific losses of peptides from low copy number proteins and 2) systematic
interrogation of all m/z channels allows detection of peptides obscured by chemical noise. A
key result of the initial PAcIFIC publication was to demonstrate that more information was
available by thorough examination of a single serum sample rather than incomplete DDA
examination of dozens of fractions. The ultimate goal of PAcIFIC analysis is to provide a
simplified, automated, direct and systematic approach for proteomic screening that is more
akin to genomic sequencing than other proteomic methods.
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Here we describe results from the application of a quantitative PAcIFIC screen to a current
problem in breast cancer treatment; tamoxifen resistant cancers. Breast cancer is the most
commonly diagnosed cancer in women and it is estimated that approximately 10% of
women will suffer from the disease at some point in their lifetime.15 Improvements in breast
cancer treatment over the last few decades have led to an overall decrease in mortality of the
disease, with adjuvant anti-estrogen therapies (e.g. tamoxifen) effectively treating a majority
of ER-positive breast cancer patients.16 Despite these successes, approximately 50 percent
of patients have intrinsic resistance to tamoxifen therapy and most of the remainder will
acquire resistance to the drug, leading to metastatic cancer.17–18 A further understanding of
the tamoxifen mechanism of action and mechanisms of intrinsic, or acquired, resistance at
the proteome level will aid in the development of modified disease treatment. As tamoxifen
resistance and agonistic functions have been observed, we asked whether we could identify
novel proteins up-regulated after tamoxifen treatment of MCF-7 breast cancer cells using the
systematic PAcIFIC proteomic screen. Here we demonstrate the importance of increased
dynamic range for identifying unique proteins by PAcIFIC14 analysis that were not
identified by DDA genome-based gas-phase fractionation (GPF),9 and the incorporation of
quantitative label-free spectral counting to identify these proteins of interest in tamoxifen
resistance.
Experimental Procedures
Unless otherwise stated, all chemicals were purchased from Sigma. Whole genome
transcriptome analysis using the Affymetrix platform with RNA from untreated and
tamoxifen-treated cells was performed by Almac Diagnostics (Craigavon, UK). Doxorubicin
and cisplatin were acquired from Calbiochem (Gibbstown, New Jersey).
Cell Culture/Xenografts/Target Validation
MCF-7 breast cancer cells (ECACC European Collection of Cell Cultures, Salisbury,
Wiltshire (UK)) were cultured in DMEM supplemented with 10% FCS in a humidified
incubator in 5% CO2 at 37°C. Cells were plated at a density of 1.5×105 cells per well in six-
well tissue culture plates 1 day prior to treatment. Tamoxifen was dissolved in DMSO to
give a concentration of 1mM. For treatment of cells, this was diluted 1:1000 in DMEM 10%
FCS to give a final tamoxifen concentration of 1µM. Cells were treated with 1µM tamoxifen
or DMSO only (control) for a total of 96 hours, with the media and tamoxifen being
replaced after 48 hours. Cells were harvested in ice cold PBS. Tamoxifen and control
incubations were performed in parallel biological duplicates.
Cell survival or death using the AGR2-negative and positive cell panel with exposure to
doxorubicin was determined using an MTT assay.19 For xenograft studies, H1299 cell
lines(American Type Culture Collection (ATCC), Manassas, VA), either anterior gradient
homolog protein 2 (AGR2)-negative or transfected to acquire AGR2,20 were processed in a
xenograft system in the absence and presence of cisplatin, as previously described.21–22
Briefly, transfected H1299 cells (5 × 106 cells / implant) were initially injected
subcutaneously into the flanks of groups of adult female nude mice to establish the
xenograft lines. Animals were at least 8 weeks old at the time of experimentation and were
maintained in negative pressure isolators (La Calhene, UK). For experiments, tumor
fragments were implanted subcutaneously into both flanks of nude mice and allowed to
grow to 4–6 mm in diameter (over a period of approximately 1 month). Animals were then
allocated to cisplatin treatment (5 mg/kg ; i.p.) or control (5 mice/group) groups and
treatment was commenced (defined as day 0). Groups contained 8–10 tumors. Tumor size
was measured twice weekly using calipers and the volume calculated according to the
formula π/6 × length × width2. Relative tumor volumes (%) were then calculated for each
individual tumor by dividing the tumor volume on day t (Vt) by the tumor volume on day 0
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(V0) and multiplying by 100. Mean tumor volumes were then obtained. Ethical approval was
granted by the University of Edinburgh ethical review committee and experiments were
conducted according to UKCCCR guidelines under a Home Office license.23
For western blot analysis cells were lysed in the following buffer: 150mM NaCl, 50mM Tris
HCl pH 8.0, 50mM NaF, 5mM EDTA, 1% NP-40 plus 1:100 phosphatase inhibitor cocktail
and 1:100 protease inhibitor cocktail. AGR2 was detected using a polyclonal antibody to
AGR2 raised in rabbit (Moravian Biotechnology Ltd., Brno Czech Republic).
For RT-PCR, total RNA from cells was extracted and purified using an RNeasy Mini kit
(Qiagen, Hilden, Germany) with QIAshredder to homogenize lysate. cDNA was generated
using the Omniscript RT kit (Qiagen, Hilden, Germany) and finally AGR2 and GAPDH
were detected by PCR using HotStarTaq DNA polymerase (Qiagen, Hilden, Germany) with
the following oligonucleotide primers; AGR2 forward:
GCTCCTTGTGGCCCTCTCCTACAC, AGR2 reverse:
ATCCTGGGGACATACTGGCCATCAG. GAPDH forward:
GTCAGTGGTGGACCTGACCT, GAPDH reverse ACCTGGTGCTCAGTGTAGCC.
Mass spectrometry
After cells were lysed in 50 mM ammonium bicarbonate by alternating three cycles of
sonication and cooling, insoluble fragments were removed by centrifugation. Protein
concentration was determined with a standard BCA assay, and an excess of over 100 µg
from each sample were allotted for digestion. Urea was added to a final concentration of
6M, and 7 uL of 1.5 M Tris pH 8.8 were added to maintain a basic solution during reduction
in the 100 uL of solution. Proteins were reduced for 1 hr at 37° C with a final concentration
of 5 mM tris(2-carboxyethyl)phosphine. Cysteine residues were alkylated by the addition of
20 uL of 200 mM iodoacetamide and incubation for 1 hr in the dark, followed by the
addition of 20 uL of 200 mM dithiothreitol and one-hour incubation. Samples were diluted
with 900 µL of 50 mM ammonium bicarbonate and sequencing-grade trypsin was added at a
protein to enzyme ratio of 1:50. Digestion proceeded overnight at room temperature.
Samples were desalted using a Vydac silica C18 macrospin column (The Nest Group,
Southborough, MA).
Two types of HPLC-MS/MS data acquisition schemes were run in duplicate: 1) DDA
genome-based GPF9 and 2) a modified version of the DIA PAcIFIC method.14. All
acquisitions were carried out using either the linear ion trap (LTQ) of a LTQ-Orbitrap
hybrid mass spectrometer or a standalone LTQ mass spectrometer (Thermo Scientific Corp.,
San Jose, CA). Modifications to the published PAcIFIC analysis included increasing the
mass range covered per method file from 15 to 22.5 m/z units. Consecutive scans remained
1.5 units apart with an isolation width of 2.5 m/z as previously described. Genome-based
GPF was conducted using MS scan ranges of: 350–520, 515–690, 685–970, and 965–2000
m/z. For all acquisition methods, approximately 1 µg of peptides per injection was separated
online using home-packed columns (0.75 µm i.d. × 11cm; 100Å Magic C18AQ (Michrom
Bioresources, Auburn, CA)) and a Nano-Acquity (Waters, Milford, MA) or 1100 binary
HPLC (Agilent, Santa Clara, CA) with a linear gradient of 5–35% ACN over 60 minutes.
For each full PAcIFIC analysis 45 µg of total peptide digest was required per sample/
replicate. Electrospray ionization voltage was applied via a gold wire and liquid microtee
junction.24 All ions were measured in positive mode and source parameters were optimized
for each system using the manufacturer-suggested tune solution. Automatic Gain Control
(AGC) was used to maintain constant ion populations at 3e4 and 1e4 for precursor ion scans
(MS) and CID fragment ion scans, respectively.
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Protein Identification/Quantification
Raw data files were converted to the mzXML format using ReAdW.exe version 4.0.2
(Institute for Systems Biology, Seattle, WA) with default parameters. Proteins were
identified by SEQUEST,25 version 27, specifying optional cysteine alkylation in the search
parameter file. Other search parameters included: precursor mass tolerance 3.75 Da for DIA
and 2.1 Da for DDA, fragment ion mass tolerance 1 Da (default), two allowed missed
cleavages, and one required enzyme specific terminus. Data was searched against the
Human International Protein Index (IPI) database version 3.49 which contains a total of
74017 proteins. Identifications were filtered at a ≥ 0.95 protein and peptide probability using
PeptideProhpet,26 and proteins with only one peptide identified were excluded, allowing for
a false positive rate of ≤ 0.7%. Identifications resulting from protein isoforms were
considered redundant unless a unique peptide was identified to a given secondary isoform.
Relative protein levels were determined using spectral counting as previously described
using the same ≥ 0.9 probability.27 Briefly, spectral counting uses the number of peptide
tandem mass spectra identified for each peptide from a given protein to estimate abundance
of that protein relative to all others present in the sample. To adapt the output of spectral
counting for both rational gas phase fractionation and PAcIFIC datasets, the spectral counts
for each protein were summed for all data over the complete m/z range analyzed per sample
for each replicate. The final protein spectral count was the accumulation of all spectral
counts from all PAcIFIC, or genome based GPF, HPLC MS runs for one analytical cycle. A
t-test was used to determine if the difference between relative levels were statistically
significant with a cutoff of greater than 0.05, and of this statistically significant set,
identification in both analytical duplicates in either control or tamoxifen-treated was
required.
Results
Global Protein Identifications
Total cell lysates from MCF-7 cells +/− tamoxifen treatment were prepared for proteomic
profiling as described in the experimental section. Data were acquired in duplicate using two
direct, but different, shotgun proteomic discovery methods that eschew sample pre-
fractionation: 1) DDA genome based GPF analysis with the following m/z regions 350–520,
515–690, 685–970, and 965–2000 and 2) DIA PAcIFIC analysis where each m/z channel
from 400 to 1400 m/z (e.g. 400, 401.5, 403, 404.5 …) was examined by CID. For both
methods, database search identified proteins were filtered at a minimum probability of 0.95
with two or more peptide tandem mass spectral matches required for positive protein
identification. From these experiments the PAcIFIC method identified 1791 proteins in the
control sample and 1631 proteins from tamoxifen-treated cells. From the list of proteins
identified in the control cells 501 were unique whereas 341 were unique to the tamoxifen
treated cell proteome, for a total of 2132 proteins identified from the two conditions. While
the analytical efficiency (proteins identified/injection) of genome-based GPF analysis was
four-fold greater than that of PAcIFIC, only half as many proteins were identified; i.e. 841
proteins from the control and 785 proteins from tamoxifen-treated cells. Fewer unique
proteins were also identified by GPF in the control versus tamoxifen treated cells; i.e. 276
versus 220 respectively. Notably, using the DIA PAcIFIC strategy, we identified more than
twice the number of peptides per protein and more than twice as many proteins compared to
the genome-based DDA GPF method. While the PAcIFIC method is only 36% as efficient
as genome-based GPF in terms of proteins identified per HPLC-MS/MS analysis (i.e. 66
versus 24), the increase in individual protein sequence coverage to an average of three,
rather than two peptides/protein, added confidence to quantification by spectral counting
discussed below. Additionally, PAcIFIC analysis identified approximately three times more
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transcription factors than the previous studies (Umar et al) and twice as many as the DDA
GPF results described above (Table 1).
Quantitative Analysis
Spectral counting was used on all HPLC-MS/MS data sets to identify differences in relative
levels of protein expression between +/− tamoxifen-treated MCF-7 cells (Table 2).
Quantitative results from genome-based GPF identified 19 proteins with a statistically
significant change in expression in the tamoxifen-treated cells, three of which were also
corroborated by PAcIFIC analysis (Supplemental Table 1). The PAcIFIC method, however,
identified 83 proteins as differentially expressed at a statistically significant level in the
tamoxifen-treated MCF-7 cells with 23 and 60 proteins at higher and lower levels,
respectively, compared to control (Table 2). The number of spectral counts per protein was
equal to, or significantly higher, for DIA PAcIFIC analysis than the DDA genome based
GPF results (Figure 1). The higher spectral counts derived from PAcIFIC then provided a
more rigorous statistical analysis for the identification of statistically significant changes in
protein abundance.
Target Validation
One of the most up-regulated proteins after tamoxifen treatment identified in this study was
AGR2 (Table 2), a recently discovered protein implicated in cell migration, limb
regeneration, p53 down-regulation, poor survival rates, and metastasis.20,28–32 Having
observed that a relatively novel pro-oncogenic protein was induced by tamoxifen treatment,
we focused biochemical validation on investigating whether AGR2 might function as a
tamoxifen agonistic or antagonistic factor. The treatment of cells with tamoxifen showed, as
expected, that AGR2 is induced over time using immunochemical methods (Figure 2A),
which correlated with elevations in AGR2 mRNA levels using RT-PCR (Figure 2B).
However, despite elevated AGR2 mRNA in a microarray study (data not shown), a parallel
transcriptomic screen did not identify AGR2 as a significant outlier that would warrant
evaluation (Supplemental Table 2).
Common assays used to evaluate the function of a cancer gene involve determining whether
the gene can affect cell survival or circumvent drug-induced cell growth inhibition. Using
cells stably transfected with an AGR2 gene, or vector control,20 we demonstrated that the
AGR2 gene can promote resistance to cell death induced by the common DNA damaging
agent doxorubicin (Figure 3). Further, although these two cell panels (vector control and
AGR2) do not show obvious differences in the growth rate in xenograft animal models, the
cells expressing the AGR2 gene confer resistance to cisplatin (Figure 4). Thus, by
demonstrating that AGR2 can mediate drug resistance using in vitro and in vivo xenograft
model systems, we further validated this PAcIFIC generated hypothesis.
Discussion
Tamoxifen has provided substantial improvements in disease management, however it has
also been associated with agonistic effects involving either intrinsic, or acquired, resistance.
Previous studies comparing tamoxifen-induced proteomes have primarily used 2-DE
methods with subsequent HPLC-MS/MS, or matrix assisted laser desorption ionization mass
spectrometry (MALDI), for identification of proteins present in each stained spot.33–34 As
expected, 2-DE methods tend to identify fewer proteins than shotgun proteomic methods, in
part, because of loading capacity issues with the first dimension. Recently, the first paper
using shotgun proteomics to characterize tissues from tamoxifen-sensitive and tamoxifen-
resistant tumors using an accurate mass and time (AMT) tag approach was published.35 The
AMT shotgun proteomic method consists of two phases. In the first phase, an extensive
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library of proteins identified by DDA-based HPLC-MS/MS of peptides is recorded in a
library according to mass and elution time using any available material. In the second phase,
conducted on samples of limited abundance using only precursor ion scans, the AMT
peptide library of previously identified proteins is used to identify proteins by comparison to
the library. Thus, the method can be quite sensitive and this particular AMT study identified
2556 proteins from 51 tumor samples whereas the prior 2-DE studies identify only between
12–20 proteins.
In an effort to analyze proteomic samples more efficiently, our laboratory has focused
recently on developing shotgun proteomic methods that eschew fractionation prior to HPLC-
MS analysis. Specifically, one of these methods, PAcIFIC, has been shown to be capable of
detecting proteins an order of magnitude lower in abundance than standard methods that
fractionate peptides prior to DDA HPLC-MS/MS analysis (Panchaud et al., 2009) and to
detect proteins across the full dynamic range of yeast (Panchaud et al., 2011).36 Here
PAcIFIC was employed to identify tamoxifen-induced proteins for the evaluation of
agonistic or antagonistic effects. In this study, we used our prior optimized DDA genome-
based GPF method (Scherl et al., 2008) and the newer DIA PAcIFIC method to identify
proteins in total cell lysates from MCF-7 cells +/− tamoxifen treatment. While the analytical
efficiency of proteins identified per HPLC-MS/MS analysis is four-fold greater for the
genome based GPF versus the PAcIFIC method, the number of proteins identified reaches a
plateau beyond which additional analyses do not result in further proteins being identified.9
As we have shown, this is most likely due to inefficient DDA sampling and, in fact, previous
results demonstrated that the GPF method worsened as the m/z range sampled was reduced
to ~ 50 m/z, suggesting a fundamental problem with DDA sampling from too narrow an m/z
range that prevented further refinement of this approach.9,37 This led to development of the
PAcIFIC method that systematically queries peptides present in all m/z channels without
regard for the presence/absence of a precursor ion. While this feature reduces analytical
efficiency, it extends dynamic range to a group of peptides not detectable by DDA methods
because they are obscured by baseline chemical noise or high intensity ion signals.
The lower efficiency of PAcIFIC analysis indicates that sampling has reached the bottom of
available mass spectrometric dynamic range; e.g. depending on complexity between 15–
30% of peptides identified can come from peptides with no detectable precursor ion which
we previously defined as orphan peptides (Panchaud et al., 2009). The importance of more
complete proteomic profiling provided by PAcIFIC is exemplified by the case of AGR2
which was identified in both the DDA GPF and DIA PAcIFIC datasets, but only PAcIFIC
detected a significant change in expression. This detection of AGR2 as having a significant
change in expression post tamoxifen treatment by PAcIFIC was due to the higher spectral
count values in the PAcIFIC data than were detected in the GPF data. This highlights an
additional benefit of the PAcIFIC method which detects more peptides per protein (Table 1)
than the DDA GPF method and thus allows for more accurate quantification by spectral
counting (Table 3) and extension of the detectable quantitative dynamic range. Finally, we
note that when sample is limited (e.g. < 24 HPLC-MS/MS runs are possible) that use of the
genome based GPF method is recommended over PAcIFIC analysis because of the higher
efficiency.
In our DIA PAcIFIC data, but not the DDA GPF data, one of the most significantly induced
proteins, AGR2, stood out as a recently identified pro-oncogenic protein. Given the growing
interest in AGR2 in cancer research, we included a novel biological validation to affirm the
importance of AGR2 and/or its pathway partners as a potential anti-cancer drug target. This
investigation into the importance of the up-regulation of AGR2 on cell viability and
tamoxifen agonistic effects demonstrated that AGR2 is directly linked to cell viability and
that tamoxifen induction of AGR2 protein occurs at the transcriptional level (Figures 2a and
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2b). For example, it has been demonstrated previously that AGR2 can induce metastasis in
animal models and mediate limb regeneration.28–31 AGR2 can also predict poor prognosis
when over-expressed in prostate and breast cancers.32,38 Furthermore, the AGR2 gene can
function as a drug resistance factor in model cancer systems (Figure 3 and 4), suggesting
that it may provide agonistic effects from tamoxifen if it were induced in vivo in response to
the drug.
Of the other proteins identified at elevated levels after tamoxifen treatment in the PAcIFIC
dataset (Table 2), several besides AGR2 are associated with cancer cell growth. One of the
most up-regulated proteins, Aminopeptidase B, catalyzes the hydrolysis of amino acids, and
inhibition of it would disrupt protein degradation, interfering with cell turnover. Research
studies on the inhibition of aminopeptidases as cancer therapeutics have already begun in
myeloma cell lines.39 Clusterin precursor was also identified as up-regulated due to
tamoxifen treatment, and recent studies demonstrate that inhibition of clusterin, a pro-
apoptotic protein, increased the sensitivities to tamoxifen treatment and is at higher levels in
cell lines resistant to anti-estrogen treatments.40–41 Septins have also been associated with
cancer and Septin 2, identified as up-regulated post tamoxifen treatment in this study, is
required for cytokinesis and binds to actin. For example, Septin 9 is much more abundant in
breast cancer cells than in normal cells, and has been shown to enhance cell growth and
motility.42 Finally, we observed an overall up-regulation of proteins associated with the
cytoskeleton and cell motility in our data, perhaps suggesting a link between tamoxifen
treatment, AGR2, Septins and cancer.
Despite the differences in sample source and analytical methods used to acquire data, there
was a 60% overlap between proteins identified in the +/− tamoxifen-treated MCF-7 cells in
the present study and the clinical samples of Umar et al. We feel this, as well as the fact that
PAcIFIC profiling identified almost three times as many transcription factors (Table 1)
compared to the number identified in the DDA-based Umar study35, provide further
evidence in favor of the DIA-based proteome profiling. Additionally, we note that AGR2, a
protein we detected and confirmed a pro-survival role in our study, was not identified in the
Umar AMT study. Regardless, we believe that the two studies provide complementary
information on tamoxifen biochemistry due to i) the differences between heterogeneous
clinical samples and homogeneous cell lines as well as the differences between the treatment
regimens of patients and selectively treated cell lines, and ii) differences in the analytical
methods used, which identified roughly the same number of proteins. Importantly, because
the DIA PAcIFIC method screens for peptides in each m/z channel, regardless of precursor
ion signal, effective dynamic range is extended. Thus, PAcIFIC could be used to extend the
dynamic range of AMT databases because the classic DDA approach used to build an AMT
library selects only peptide ions that are above the chemical noise threshold limiting the
dynamic range of detection. Illustrating this point, we note that the Umar et al. AMT study
on clinical samples, did not identify AGR2 as an important regulator of tamoxifen treatment,
suggesting that i) the DDA methods used to create the AMT database do not probe a
proteome as deeply as the DIA PAcIFIC method and/or ii) there is a role for proteomic
analysis of more homogeneous cancer cell lines alongside heterogeneous clinical studies.
Regardless of these deficiencies, the AMT method excels at analysis of clinical samples of
limited availability because proteins are identified from a single HPLC-MS experiment
through comparison to the predefined AMT peptide library. The work in this manuscript
required 45 µg of protein, 1 µg for each of the 45 LCMS acquisitions, per sample for
analysis; however, since then the PAcIFIC method has been further optimized. Specifically,
the m/z range covered and the number of channels in each acquisition were increased due to
the faster scan speeds of the LTQ Velos, effectively reducing the number of LCMS
acquisitions and amount of protein required for a complete PAcIFIC analysis.36 Currently, a
full PAcIFIC analysis requires only ~ 20 µg of protein, which is more similar to the number
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needed to set up an AMT database than to profile clinical samples, but this number will fall
as new instrumentation is developed and ion trap scan speeds increase; e.g. the LTQ-Velos
scans roughly twice as fast as the prior model by incorporating an ion funnel prior to the ion
trap.43–46 Thus, we suggest that a future clinical approach to proteome profiling would
combine the advantages of limited sample requirements to read identifications from an AMT
database with the greater detectable dynamic range provided by PAcIFIC. Finally, we note
that similar to building an AMT database, SRM databases which are used to provide
quantitative data by following specific peptide fragment ion transitions are available directly
from any given PAcIFIC data set for most, if not all, peptides present in a sample.47
In summary, cancer is proving to be a tissue-specific disease and novel approaches are
required to improve drug responses and disease management in patients. While most of the
current highly sensitive proteomic approaches can be used to identify differential protein
expression in drug-resistant and drug-sensitive clinical cancers to identify putative drug-
resistant or prognostic factors, they have a limited detectable dynamic range by use of the
DDA process that fails to select most of the low intensity ion signals. As we have shown
here, use of a simple DIA proteomic profiling approach, PAcIFIC, extended dynamic range
of detection allowing an important pro-survival protein, AGR2, to be detected as up-
regulated in MCF-7 cells post tamoxifen treatment, a fact we then confirmed in cell based
assays. AGR2 has also been implicated in other types of cancer, including pancreatic and
prostate, where AGR2 is thought to play a role in predicting poor prognosis and metastatic
growth. Furthermore, the lack of identification of AGR2, known to be important in
tamoxifen response, at statistically significant levels using transcriptomic and standard DDA
shotgun proteomic methods highlights the need for continued development of more
thorough proteome profiling methods. We note that, while the ion trap instrumentation used
in this study required two days of continuous MS use for a single PAcIFIC experiment, that
the use of ion funnels to decrease ion trap fill times (e.g. the LTQ Velos, ThermoFisher)
now allows the same experiment to be conducted in only 1.5 days. We expect that this trend
toward even faster scanning mass spectrometers will continue and from this trend more
thorough proteome screens that eventually rival transcriptomic screens for speed and
sensitivity will emerge. Thus, we feel that the simplicity and directness of PAcIFIC holds
promise for more routine screening of primary clinical material that would complement
whole genome transcriptome and whole genome cancer sequencing.
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Figure 1.
Spectral count per protein with DDA GPF vs PAcIFIC analysis for all mutual protein
identifications.
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Figure 2.
Induction of AGR2 by tamoxifen. A) Protein lysate immunoblotted for AGR2 protein in
response to tamoxifen treatment B) AGR2 mRNA levels in response to tamoxifen treatment
(GAPDH control).
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Figure 3.
AGR2 mediates in vitro resistance to doxorubicin. H1299 cells expressing AGR2 or control
cells were incubated with increasing concentrations of doxorubicin and processed for cell
viability using the MTT assay.
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Figure 4.
AGR2 Mediates Resistance of Xenograft cells to cisplatin administration. Isogenic cells
with vector control (A), or stably expressed AGR2 (B), were grown in xenograft systems
and cisplatin (CDDP) was administered over the indicated time course.
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